Overview

Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
Objectives: To determine maximum tolerated dose of CPT-11 when administered following Temodar plus O6-benzylguanine To characterize any toxicity associated w combo of CPT-11 + Temodar plus O6-BG To observe pts for clinical antitumor response when treated w combo of CPT-11 + Temodar + O6-BG
Phase:
Phase 1
Details
Lead Sponsor:
Duke University
Collaborators:
Keryx / AOI Pharmaceuticals, Inc.
Pharmacia
Treatments:
Anticonvulsants
Camptothecin
Carbamazepine
Convulsants
Dacarbazine
Irinotecan
O(6)-benzylguanine
Phenobarbital
Phenytoin
Temozolomide